The Goldilocks Dilemma in AML: Too Young and Fit, but Not Young and Fit Enough

Acute myeloid leukemia (AML) is principally a disease of older patients, with a median age at diagnosis of 68 years1. In 2020, the landmark VIALE-A trial led to full FDA approval of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) for newly diagnosed AML patients age 75 or older, or patients younger than 75 with one of several qualifying co-morbidities2. In relatively short order, a new standard-of-care was implemented across the world for the majority of AML patients over the age of 75.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Editorial Source Type: research